<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733301</url>
  </required_header>
  <id_info>
    <org_study_id>17100</org_study_id>
    <secondary_id>I4V-MC-JAIY</secondary_id>
    <secondary_id>2018-001726-26</secondary_id>
    <nct_id>NCT03733301</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis</brief_title>
  <acronym>BREEZE-AD7</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of baricitinib in
      combination with topical corticosteroids (TCS) in participants with moderate to severe atopic
      dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Actual">August 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 with a ≥ 2 Point Improvement</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Eczema Area and Severity Index 75 (EASI75)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving EASI75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving EASI90</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving EASI90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline on EASI Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Percent change from baseline on EASI Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving SCORAD75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving a 4-Point improvement on the Itch NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the score of item 2 of the ADSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Skin Pain NRS</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in skin pain NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving EASI50</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving EASI50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving IGA of 0</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving IGA of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SCORAD</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in SCORAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving SCORAD90</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving SCORAD90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Surface Area (BSA) Affected</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in BSA affected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Developing Skin Infections Requiring Antibiotic Treatment</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants developing skin infections requiring antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Gram Quantity of TCS Use (Tube Weights)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Mean gram quantity of TCS use (tube weights)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Itch NRS</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Percent change from baseline in Itch NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the total score of the POEM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Patient Global Impression of Severity—Atopic Dermatitis (PGI-S-AD) Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the PGI-S-AD score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Hospital Anxiety Depression Scale (HADS)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the HADS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the DLQI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the WPAI-AD questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from Baseline on the EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days without Use of Background TCS</measure>
    <time_frame>Baseline through 16 Weeks</time_frame>
    <description>Mean number of days without use of background TCS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally in combination with topical corticosteroids. Placebo administered orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally in combination with topical corticosteroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical corticosteroid</intervention_name>
    <description>Administered as standard-of-care.</description>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been diagnosed with moderate to severe atopic dermatitis for at least 12 months.

          -  Have had inadequate response to existing topical (applied to the skin) medications
             within 6 months preceding screening.

          -  Are willing to discontinue certain treatments for eczema (such as systemic and topical
             treatments during a washout period).

          -  Agree to use emollients daily.

        Exclusion Criteria:

          -  Are currently experiencing or have a history of other concomitant skin conditions
             (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory,
             or unstable skin disease that requires frequent hospitalizations and/or intravenous
             treatment for skin infections.

          -  A history of eczema herpeticum within 12 months, and/or a history of 2 or more
             episodes of eczema herpeticum in the past.

          -  Participants who are currently experiencing a skin infection that requires treatment,
             or is currently being treated, with topical or systemic antibiotics.

          -  Have any serious illness that is anticipated to require the use of systemic
             corticosteroids or otherwise interfere with study participation or require active
             frequent monitoring (e.g., unstable chronic asthma).

          -  Have been treated with the following therapies:

               -  Monoclonal antibody for less than 5 half-lives prior to randomization.

               -  Received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4
                  weeks prior to randomization.

               -  Received any parenteral corticosteroids administered by intramuscular or
                  intravenous (IV) injection within 6 weeks prior to planned randomization or are
                  anticipated to require parenteral injection of corticosteroids during the study.

               -  Have had an intra-articular corticosteroid injection within 6 weeks prior to
                  planned randomization.

          -  Have high blood pressure characterized by a repeated systolic blood pressure &gt;160
             millimeters of mercury (mm Hg) or diastolic blood pressure &gt;100 mm Hg.

          -  Have had major surgery within the past eight weeks or are planning major surgery
             during the study.

          -  Have experienced any of the following within 12 weeks of screening: venous
             thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart
             disease, stroke, or New York Heart Association Stage III/IV heart failure.

          -  Have a history of recurrent (≥2) VTE or are considered at high risk of VTE as deemed
             by the investigator.

          -  Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver
             disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative
             disease or neuropsychiatric disorders or any other serious and/or unstable illness.

          -  Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
             infection including herpes zoster, tuberculosis.

          -  Have specific laboratory abnormalities.

          -  Have received certain treatments that are contraindicated.

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Investigaciones Metabólicas (CINME) - Comite</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion CIDEA</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Neumonología y Dermatología</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1425BEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriahue Medicina Interdisciplinaria</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1425DKG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parra Dermatología</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woden Dermatology</name>
      <address>
        <city>Phillip</city>
        <state>Australian Capital Territory</state>
        <zip>2606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin &amp; Cancer Foundation Australia</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research Pty Ltd</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials SA Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Foundation Inc.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Dermatology</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologisches Zentrum Osnabrück Nord</name>
      <address>
        <city>Bramsche</city>
        <state>Niedersachsen</state>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen - UKA</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TFS Trial Form Support GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Univ. Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Ospedale San Martino di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS 8</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawashima Dermatology Clinic</name>
      <address>
        <city>Ichikawa-shi</city>
        <state>Chiba</state>
        <zip>272-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Soleil Miyata Dermatology Clinic</name>
      <address>
        <city>Matsudo-shi</city>
        <state>Chiba</state>
        <zip>271-0092</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamano Dermatological Clinic</name>
      <address>
        <city>Dazaifu</city>
        <state>Fukuoka</state>
        <zip>818-0104</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tashiro Dermatological Clinic</name>
      <address>
        <city>Iizuka-city</city>
        <state>Fukuoka</state>
        <zip>820-0040</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shibaki Dermatology Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>006 0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Skin Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Square Dermatology and Allergology</name>
      <address>
        <city>Nishi-ku, Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>220-6208</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshioka Dermatology Clinic</name>
      <address>
        <city>Neyagawa-shi</city>
        <state>Osaka</state>
        <zip>572-0838</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senri-Chuo Hanafusa Dermatology Clinic</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-0085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JA Shizuoka Kohseiren Enshu Hospital</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>430-0929</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iidabashi Clinic</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Teishin Hospital</name>
      <address>
        <city>Chiyoda-Ku</city>
        <state>Tokyo</state>
        <zip>102-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosono Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oizumi Hanawa Clinic</name>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>178-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamate Dermatological Clinic</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <zip>169-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tachikawa Dermatology Clinic</name>
      <address>
        <city>Tachikawa-shi</city>
        <state>Tokyo</state>
        <zip>190-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shirasaki Clinic</name>
      <address>
        <city>Takaoka-shi</city>
        <state>Toyama</state>
        <zip>9330871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan-si</city>
        <state>Gyeonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <state>Korea</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermed Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED</name>
      <address>
        <city>Warszawa</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Evimed</name>
      <address>
        <city>Warszawa</city>
        <zip>02-625</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Gran Canaria Dr. Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University- Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Taipei</name>
      <address>
        <city>Taipei</city>
        <zip>10508</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou</name>
      <address>
        <city>Taoyuan, (r.o.c.)</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/atopic-dermatitis/JAIY</url>
    <description>A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eczema</keyword>
  <keyword>atopic eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <pending_results>
    <submitted>July 24, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

